Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Solid Tumors × dapagliflozin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 5 Solid Tumors 1 Prostatic Neoplasms 1 Polycystic Ovary Syndrome 1 Pediatric Brain Tumor 1 Lung Neoplasms 1 Inflammation 1 Hyperinsulinism 1 Heart Failure 1 Cardiotoxicity 1 Adenocarcinoma of Lung 1

Interventions

Cetuximab 4 Injections 3 pembrolizumab 2 Bevacizumab 2 taxane 1 spartalizumab 1 ribociclib 1 pralsetinib 1 olaparib 1 ipatasertib 1 inavolisib 1 fludarabine phosphate 1 fludarabine 1 entrectinib 1 encorafenib 1 dapagliflozin 1 cemiplimab 1 binimetinib 1 atezolizumab 1 amivantamab 1 alectinib 1 Immunotherapy, Adoptive 1 IFL protocol 1 Folfox protocol 1 Cyclophosphamide 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07018622 2026-03-11

DAPA-ARMOR

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Phase 2 Recruiting

Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡